Drug Approval | February 21, 2022
Strides receives USFDA approval for Amantadine Hydrochloride capsules
To be marketed by Strides Pharma Inc. in the US market
To be marketed by Strides Pharma Inc. in the US market
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The grants are expected to be received over the next three years, commencing March 2022
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Subscribe To Our Newsletter & Stay Updated
